Get startedLog in
    Picture of Aclaris Therapeutics logo

    ACRS — Aclaris Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapMomentum Trap
    All News

    Brief: Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052

    Picture of Aclaris Therapeutics logoAclaris Therapeutics
    24/02/2026 12:18
    Feb 24 (Reuters) - Aclaris Therapeutics Inc ACRS.O:

ACLARIS THERAPEUTICS INITIATES PHASE 1B PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH ASTHMA WITH ITS NOVEL BISPECIFIC ANTI-TSLP/IL-4RΑ ANTIBODY ATI-052

ACLARIS THERAPEUTICS INC - TOP LINE RESULTS EXPECTED IN SECOND HALF OF 2026

ACLARIS THERAPEUTICS INC - PHASE 2B PROGRAM ENCOMPASSING ASTHMA AND ATOPIC DERMATITIS EXPECTED TO START IN H2 2026

Source text: ID:nGNX5Ywq8Y

Further company coverage: ACRS.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Aclaris Therapeutics

    See all news